lamotrigine nicotinate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: lamotrigine nicotinate
• 英文别名: 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine;pyridine-3-carboxylic acid
• 化学式: C₆H₅NO₂*C₉H₇Cl₂N₅
• 分子量: 379.205
• InChiKey: YMNDJPJSNJERFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.79
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  141
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  烟酸 、 那蒙特金 以 甲醇 为溶剂， 反应 48.0h， 生成 lamotrigine nicotinate
  参考文献：
  名称：

  Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine

  摘要：

  In this contribution. we describe how the supramolecular synthon approach call be used for discovery of novel crystal forms and For enhancing the relevant preclinical properties Of 1 IOW solubility antiepileptic drug, lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine). Ten novel crystal forms are reported: lamotrigine methylparaben cocrystal form I (1:1) (1), lamotrigine methylparaben cocrystal form II (1:1) (2), lamotrigine nicotinamide cocrystal (1:1) (3), lamotrigine nicotinamide cocrystal monohydrate (1:1:1) (4), lamotrigine saccharin salt (1:1) (5), lamotrigine adipate salt (2:1) (6), lamotrigine malate salt (2:1) (7), lamotrigine nicotinate dimethanol solvate (1:1:2) (8), lamotrigine dimethanol solvate (1:2) (9), ad lamotrigine ethanol monohydrate (1:1:1) (10). A selected set of the reported crystal forms Were studied to determine their dissolution rate, solubility, and pharmacokinetic behavior. The solubilities were measured in aqueous media and in acidified aqueous media (pH = 1). It was observed that 5 and 2 exhibited the highest concentration in the aqueous media and acidified aqueous media, respectively. In the pharmacokinetic study, the serum concentration of lamotrigine, measured in Sprague-Dawley rats, reached the highest level after a single-dose oral administration of 5.

  DOI：

  10.1021/cg901010v

文献信息

• [EN] CRYSTALLINE FORMS OF LAMOTRIGINE<br/>[FR] FORMES CRISTALLINES DE LAMOTRIGINE
  申请人：THAR PHARMACEUTICALS

  公开号：WO2009061513A1

  公开（公告）日：2009-05-14

  The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

  该发明涉及拉莫三嗪的新型晶体形式。与纯拉莫三嗪相比，这些新型晶体形式的拉莫三嗪具有改进的溶解性和体内吸收特性。这些新型晶体形式的拉莫三嗪在给予受试者时，与纯拉莫三嗪相比，可以显著提高血液中拉莫三嗪的浓度。这些新型晶体形式的拉莫三嗪还提供了一个较慢、稳定的拉莫三嗪血液浓度逐渐增加的过程，适合体内持续释放拉莫三嗪，与纯拉莫三嗪相比。
• Crystalline Forms of lamotrigine
  申请人：Hanna Mazen

  公开号：US20090176787A1

  公开（公告）日：2009-07-09

  The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

  本发明涉及拉莫三嗪的新型晶体形式。这些拉莫三嗪的新型晶体形式相比纯拉莫三嗪具有更好的溶解和体内吸收特性。这些拉莫三嗪的新型晶体形式在给予受试者时，血液中的拉莫三嗪浓度显著增加，相比纯拉莫三嗪。这些拉莫三嗪的新型晶体形式也提供了更缓慢、稳定的拉莫三嗪血液浓度积累，适用于体内持续释放拉莫三嗪，相比纯拉莫三嗪。
• US8486927B2
  申请人：——

  公开号：US8486927B2

  公开（公告）日：2013-07-16
• Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine
  作者：Miranda L. Cheney、Ning Shan、Elisabeth R. Healey、Mazen Hanna、Lukasz Wojtas、Michael J. Zaworotko、Vasyl Sava、Shijie Song、Juan R. Sanchez-Ramos

  DOI：10.1021/cg901010v

  日期：2010.1.6

  In this contribution. we describe how the supramolecular synthon approach call be used for discovery of novel crystal forms and For enhancing the relevant preclinical properties Of 1 IOW solubility antiepileptic drug, lamotrigine (6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine). Ten novel crystal forms are reported: lamotrigine methylparaben cocrystal form I (1:1) (1), lamotrigine methylparaben cocrystal form II (1:1) (2), lamotrigine nicotinamide cocrystal (1:1) (3), lamotrigine nicotinamide cocrystal monohydrate (1:1:1) (4), lamotrigine saccharin salt (1:1) (5), lamotrigine adipate salt (2:1) (6), lamotrigine malate salt (2:1) (7), lamotrigine nicotinate dimethanol solvate (1:1:2) (8), lamotrigine dimethanol solvate (1:2) (9), ad lamotrigine ethanol monohydrate (1:1:1) (10). A selected set of the reported crystal forms Were studied to determine their dissolution rate, solubility, and pharmacokinetic behavior. The solubilities were measured in aqueous media and in acidified aqueous media (pH = 1). It was observed that 5 and 2 exhibited the highest concentration in the aqueous media and acidified aqueous media, respectively. In the pharmacokinetic study, the serum concentration of lamotrigine, measured in Sprague-Dawley rats, reached the highest level after a single-dose oral administration of 5.